Recent Articles from GlobeNewswire

Q3 2026 revenue of $32.9 million; GAAP basic EPS: $(0.04)

CERRITOS, Calif., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Starling Oncology, Inc. (NASDAQ: STLN) (“STLN” or the “Company”), one of the largest value-based community oncology groups in the United States, today reported financial results for its quarter ended September 30, 2026 and updated it's full-year 2026 guidance.

The American Society of Hematology, in Partnership with D S Simon Media, Conducts Nationwide Media Tour Highlighting New Guidelines to Help Identify More People with Iron Deficiency.

LOS ANGELES, Nov. 05, 2026 (GLOBE NEWSWIRE) -- BlackLine, Inc. (Nasdaq: BL), today announced financial results for the third quarter ended September 30, 2026.

45% Revenue Increase and 44% Growth in U.S. Procedure Volume Year-to-date

Third Quarter 2026 Highlights

Q1'27 Financial Results 

SAN CLEMENTE, Calif., Nov. 05, 2026 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (Nasdaq:ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced financial results for the quarterly period ended September 30, 2026.

MediWound Announces Closing of $17.25 Million Bought Deal Offering of Ordinary Shares

DOYLESTOWN, Pa., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined cancers, today announced that Oren Gilad, Ph.D., President and Chief Executive Officer, will participate in a fireside chat and meet with investors at Guggenheim’s 3rd Annual Healthcare Innovation Conference, to be held November 9-11, 2026 in Boston, MA.

REGULATED INFORMATION

Third quarter SaaS revenue of $105.5 million, representing 26% year-over-year growth, 26% on a constant currency basisThird quarter Total revenue of $131.1 million, representing 19% year-over-year growth, 20% on a constant currency basisTotal ARR of $495.1 million, representing 27% year-over-year growth, 25% adjusted for FX

SCHAUMBURG, Ill., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Paylocity Holding Corporation (Nasdaq: PCTY), a leading provider of cloud-based HCM, Finance, and IT solutions, today announced financial results for the first quarter of fiscal 2027, which ended September 30, 2026.

- Consolidated Revenues Rose 4.9% Over the Prior-year Period, With Increases at American Place, Chamonix/Bronco Billy’s and Rising Star

GOLETA, Calif., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Aeluma, Inc. (NASDAQ: ALMU), a semiconductor company specializing in high-performance, scalable technologies for mobile, AI, defense and aerospace, robotics, automotive, AR/VR, and quantum, today announced that it will participate in the 2026 Stifel Deep Tech Summit on Monday, December 7, 2026. The event will be held in-person at the Rosewood Sand Hill Hotel in Menlo Park, CA. CEO Jonathan Klamkin, Ph.D., and CFO Christopher Stewart will be available for one-on-one meetings.

Reaffirms 2026 Outlook and Provides Preliminary 2027 Outlook

NEEDHAM, Mass., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to improve disease outcomes for patients with cancer, today announced that on November 3, 2026, the Compensation Committee of Candel’s Board of Directors granted Maria Ostrovsky, in connection with her employment as Candel’s General Counsel, stock options to purchase an aggregate of 315,000 shares of the Company’s common stock, with a per share exercise price of $8.82, which is equal to the closing price of the Company’s common stock on The Nasdaq Global Market on November 3, 2026.

MOUNTAIN VIEW, Calif., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Kodiak AI, Inc. (Nasdaq: KDK), a leading provider of Physical AI-powered autonomous vehicle technology, today announced results for the third quarter ended September 30, 2026.

Third Quarter Revenue Within Guidance Range; Profit Surpasses Expectations

Proteus™ remains on track for anticipated Q2 2027 commercial launch

LONG BEACH, Calif., Nov. 05, 2026 (GLOBE NEWSWIRE) -- SkinHealth Systems Inc. (NASDAQ: SKIN) (“SkinHealth Systems” or the "Company"), home to flagship brand Hydrafacial®, today announced financial results for the third quarter ended September 30, 2026 (“Q3 2026”).

Delivered Total and Net Investment Income of $40.6 million and $15.9 million, Respectively

HAMILTON, Bermuda, Nov. 05, 2026 (GLOBE NEWSWIRE) -- SiriusPoint Ltd. (“SiriusPoint” or the “Company”) (NYSE:SPNT), a global specialty underwriter, today announced results for its third quarter ended September 30, 2026, and entered into a loss portfolio transfer (LPT) agreement to close the chapter on its legacy portfolio.

Delivers Strong Q3 With 53% Year-Over-Year Revenue Growth Raises Full Year 2026 Revenue Guidance

Q3'26 revenue grew 12% YoY to $258 million, at the high end of our guidance range

REDWOOD CITY, Calif., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (Rezolute or the Company), a late-stage ultra-rare, metabolic disease company focused on treating refractory hypoglycemia caused by any form of hyperinsulinism (HI), today reported financial results and provided a business update for the first quarter ended September 30, 2026.

SAN FRANCISCO, Nov. 05, 2026 (GLOBE NEWSWIRE) -- iRhythm Holdings, Inc. (NASDAQ: IRTC), a leading digital health care company with a mission to create trusted solutions that detect, predict, and prevent disease, today reported financial results for the three months ended September 30, 2026.

Underlying Business Momentum Drives Strong Third Quarter PerformanceAnnounces New $30 Million Share Repurchase AuthorizationRaises Full Year 2026 Financial Outlook

WASHINGTON, Nov. 05, 2026 (GLOBE NEWSWIRE) -- IBEX Limited (“ibex”) (Nasdaq: IBEX), a global leader in outsourced business services and AI-powered customer experience solutions, today announced financial results for its first fiscal quarter ended September 30, 2026.

WEST PALM BEACH, Fla., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Sunrise Realty Trust, Inc. (Nasdaq: SUNS) (“SUNS” or the “Company”) and Southern Realty Trust Inc. (“SRT”), two commercial real estate lenders on the Tannenbaum Capital Group (“TCG”) Real Estate platform, today announced the completion of the previously announced merger of SRT with and into a wholly owned subsidiary of SUNS (the “Merger”). The Merger consolidates the two companies’ co-investments into a single, larger Nasdaq-listed commercial real estate lending platform. On a pro forma basis as of June 30, 2026, the combined company had approximately $285 million of book value (after transaction-cost adjustments), approximately $534 million of total assets and approximately $604 million of total loan commitments across 14 portfolio loans collateralized by assets located predominantly in core Southern U.S. markets. The combined company will continue to operate as Sunrise Realty Trust, Inc., and its common stock will continue to trade on Nasdaq under the ticker symbol “SUNS.”

DEER PARK, Ill., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or “the Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today reported financial results for the quarter ended September 30, 2026.

Revenue increased 12% year-over-year; homes purchased more than quadrupled; TTM marketing efficiency improved 57% and operations efficiency improved 36%.

Gross margin reaches 78%; cash used in operating activities declines 56% sequentially

Results build on preliminary Week 4 findings, in which a single dose of ATTO-1310 demonstrated rapid, deep, and durable itch relief in patients with chronic pruritus (CP) and high-itch atopic dermatitis (AD)

Received authorization in the United Kingdom and European Union to expand global first-in-human ASCEND Phase 1/2 clinical trial of CMP-002 in patients with SYNGAP1-related disorder, adding to clearances in Australia and Argentina 

DENVER, Nov. 05, 2026 (GLOBE NEWSWIRE) -- EverCommerce Inc. ("EverCommerce" or the "Company") (NASDAQ: EVCM), is a leading provider of integrated, vertically-tailored software-as-a-service solutions or services that help service-based small and medium-sized businesses run smarter and grow faster, today announced financial results for the quarter ended September 30, 2026.

ROCKVILLE, MD, Nov. 05, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today announced that the Company’s management team will participate in the following investor conferences in November:

Advancing a pipeline built entirely on the Alector Brain Carrier (ABC) blood-brain barrier platform, spanning antibody, enzyme, and siRNA programs, with AL137, Alector's lead ABC-enabled anti-amyloid beta (Aβ) antibody program for Alzheimer's disease (AD), targeting first-in-human dosing in Australia no later than April 2027.

Continued progress toward starting SC451 Phase 1/2 trial in type 1 diabetes

SOUTH SAN FRANCISCO, Calif., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced positive data from five presentations at the American Association for the Study of Liver Disease’s (AASLD) The Liver Meeting® 2026, being held November 5 – 9, 2026 in Denver, CO.

Key Q3 2026 Highlights (from Continuing Operations)

SAN JOSE, Calif., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Nutanix, Inc. (NASDAQ: NTNX), a hybrid cloud leader and AI platform company, today announced that it will report its financial results for the first quarter of fiscal year 2027, which ended October 31, 2026, after U.S. markets close on Tuesday, November 24, 2026.

Board of Directors Declared Total Dividends of $0.54 per Share for Fourth Quarter 2026 Base Dividend of $0.43 and Supplemental Dividend of $0.11 Per Share

Delivers revenue growth of 73% in the third quarter and raises full year 2026 revenue guidance

CAMPBELL, Calif., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Arteris, Inc. (Nasdaq: AIP), a leading provider of semiconductor technology for accelerating innovation in the AI era, today announced financial results for the third quarter ended September 30, 2026 and provided estimated fourth quarter and updated full year 2026 guidance.

CAMBRIDGE, Mass., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Apnimed, Inc. (Nasdaq: APMD) (“Apnimed” or the “Company”), a late-stage clinical pharmaceutical company dedicated to the discovery, development and commercialization of novel oral therapies that address the neurobiology of sleep-related breathing diseases, today announced that on November 2, 2026, the compensation committee of Apnimed’s board of directors granted 14 new non-executive employees non-qualified stock options to purchase an aggregate of 331,000 shares of the Company’s common stock under Apnimed’s 2026 Inducement Plan (the “Plan”). Each stock option granted has an exercise price per share of $15.40, which is equal to Apnimed’s closing trading price on the grant date. One fourth of the shares underlying each of the employee’s stock options will vest on the first anniversary of each employee’s start date and in equal monthly installments thereafter for the next three years, subject to such employee’s continued employment with the Company on such vesting dates.

BERKELEY, Calif., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU) today reported financial results for the third quarter of 2026.

SALT LAKE CITY, Nov. 05, 2026 (GLOBE NEWSWIRE) -- Health Catalyst, Inc. (“Health Catalyst,” Nasdaq: HCAT), a healthcare intelligence company designed to accelerate measurable improvement for health systems, today reported financial results for the quarter ended September 30, 2026.

SAN FRANCISCO, Nov. 05, 2026 (GLOBE NEWSWIRE) -- Omada Health, Inc. (Nasdaq: OMDA), the virtual between-visit healthcare provider, today reported financial results for the third quarter ended September 30, 2026.

EMERYVILLE, Calif., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (Nasdaq: KYTX), a late-stage clinical immunology company pioneering transformative therapies for people with neurologic autoimmune diseases, today announced that company management will present at the Jefferies Global Healthcare Conference in London, United Kingdom on Thursday, November 19, 2026, at 10:00 am GMT.

SOUTH SAN FRANCISCO, Calif., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products for cancer and autoimmune disease, today provided corporate updates and reported financial results for the quarter ended September 30, 2026.

AUDUBON, Pa., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal technology company, today announced its financial results for the third quarter ended September 30, 2026.

Quarterly AI Cloud Revenue Nearly Triples to $200 Million

WATERTOWN, Mass., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ: TECX) (“Tectonic” or the “Company”), a clinical-stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors (GPCRs), today announced financial results for the third quarter ended September 30, 2026, and provided an overview of recent business highlights.

Vantage transition to HHH in full effect; Howard Hughes Communities® advances asset-light strategy for real estate development and asset management platform

NEW HOPE, Pa., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) (“Orchestra BioMed” or the “Company”), a biomedical innovation company accelerating high-impact technologies to patients through strategic collaborations with market-leading global medical device companies, announced today that it has commenced an underwritten public offering of shares of its common stock (the “Offering”). All of the securities are being offered by the Company. In addition, the Company intends to grant the underwriters a 30-day option to purchase up to an additional 15% of shares of its common stock sold in the Offering at the public offering price per share, less underwriting discounts and commissions. The Offering is subject to market and other conditions, and there can be no assurance as to whether or when the Offering may be completed, or as to the actual size or terms of the Offering.

EMERYVILLE, Calif., Nov. 05, 2026 (GLOBE NEWSWIRE) -- NMI Holdings, Inc. (Nasdaq: NMIH) today reported net income of $93.5 million, or $1.23 per diluted share, for the third quarter ended September 30, 2026, compared to $105.8 million, or $1.38 per diluted share, for the second quarter ended June 30, 2026 and $96.0 million, or $1.22 per diluted share, for the third quarter ended September 30, 2025. Adjusted net income for the quarter was $93.7 million, or $1.23 per diluted share, compared to $106.0 million, or $1.38 per diluted share, for the second quarter ended June 30, 2026 and $95.7 million, or $1.21 per diluted share, for the third quarter ended September 30, 2025.

HAMPTON, N.J., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) today reported financial results for the third quarter ended September 30, 2026 and provided a corporate update.

DEER PARK, Ill., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or “the Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced preliminary results from a randomized, double-blind, placebo-controlled pilot study evaluating ET-700, its investigational extended-release zinc acetate formulation being developed to treat Wilson disease.

BOSTON, Nov. 05, 2026 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio” or the “Company”), a clinical-stage biotechnology company developing next-generation immunotherapies for KRAS-driven cancers, today reported financial results for the quarter ended September 30, 2026, and provided recent corporate and clinical updates.

DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Nov. 05, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) a biopharmaceutical company dedicated to transforming chronic disease care through innovative, patient-centric solutions for cardiometabolic and orphan lung diseases, today reported financial results for the third quarter of 2026, and provided a business update.

HOUSTON, Nov. 05, 2026 (GLOBE NEWSWIRE) -- Skyward Specialty Insurance Group, Inc. (Nasdaq: SKWD) (“Skyward Group” or the “Company”) today reported third quarter 2026 results.

BOSTON, Nov. 05, 2026 (GLOBE NEWSWIRE) -- Damora Therapeutics, Inc. (NASDAQ: DMRA) (“Damora”), a biotechnology company working to fundamentally redefine care for patients with blood disorders, today announced that it granted equity awards to five newly-hired, non-executive employees on November 1, 2026. The inducement grants were approved by Damora’s independent Compensation Committee of its Board of Directors and were made as material inducements to such individuals’ acceptance of employment with Damora in accordance with Nasdaq Listing Rule 5635(c)(4).

Delivered total revenue of $24.0 million, an increase of 10% year over year

BRISBANE, Calif., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a commercial-stage biotechnology company, today reported its business highlights and financial results for the quarter ended September 30, 2026.

Total Q3 revenue of $37.7 million, including $33.4 million in U.S. net product revenue for neffy®

Third Quarter 2026 Revenues of $471.8 Million Reflect 35.7 Percent Growth and 23.2 Percent Organic Growth Over Third Quarter 2025 Revenues of $347.6 Million

Growing dataset connects industry benchmarking with deeper insight into daily slot activity.

Shlesinger spent time with service members at four military installations across Italy, performing stand-up shows and leading comedy workshops

Vancouver, British Columbia, Nov. 05, 2026 (GLOBE NEWSWIRE) -- Apogee Minerals Ltd. (“Apogee” or the “Company”) (TSXV: APMI) announces that, pursuant to the Company’s news release dated October 26, 2026, the Company’s name change from “Apogee Minerals Ltd.” to “Northmark Metals Corp.” (the “Name Change”) will be effective on Tuesday, November 10, 2026.

Company to highlight solutions spanning advanced materials, precision components, and finished medical devices

IHL Group recognizes Toshiba’s ELERA® for leadership in the AI and architecture shaping the future of retail

As workplace violence threatens staff well-being, patient care, and financial stability, CENTEGIX highlights the organizational impact of faster emergency response

Local franchise owners bring complimentary Grand Slam breakfasts to VFW posts in four markets, ahead of free Veterans Day Grand Slams at participating Denny’s nationwide